By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm China Medical Technologies today said its molecular diagnostics sales rose nearly 33 percent year over year in its fiscal second quarter, helping to grow overall revenues about 22 percent.

For the three months ended Sept. 30, the Beijing firm's molecular diagnostics systems segment recorded revenues of RMB118.3 million ($17.8 million), compared to RMB89.2 million in the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.